Pharmaceuticals Company Announces Confirmation Study Approval For Type 1 Diabetes Treatment

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2a dose confirmation study of Tolimidone for the treatment of Type 1 Diabetes (T1D). This study has been approved by Health Canada and will be conducted as an Investigator Initiated Trial (IIT) by the University of Alberta. The forthcoming clinical trial will evaluate the efficacy and safety of Tolimidone, a drug initially developed by Pfizer Inc. for gastric ulcers but later repurposed for potential use in T1D due to promising preclinical results. $Biodexa Pharmaceuticals (BDRX.US)$